← All trials
NCT06216158
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 5, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Jun 30, 2029
- First posted
- Jan 22, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 411
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of HeidelbergLead sponsor
- Bristol-Myers SquibbCollaborator
- SanofiCollaborator
- University of HeidelbergOfficial
- Julius-Maximilians UniversityCollaborator
- Koordinierungszentren für Klinische Studien bzw. Zentren für klinische StudienCollaborator
- University of HeidelbergSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.